Theranostics · 2024 · 22 citations · 25 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCancer NanomedicineCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmunotherapy For Breast CancerNanomedicineAntigen-specific T Cell ResponsesCancer NanotherapyImmune Checkpoint Inhibitor TherapyNanoparticle-based ImmunotherapyPd-1 SignalingProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Cell Death Protein 1 InhibitorsTriple-negative Breast Cancer Immunotherapy
The integration of RmPLH with PD-1 inhibitors substantially amplifies ICD, fostering robust antigen-specific T cell immunity and offering a promising therapeutic strategy for TNBC. This study represents a pioneering application of Pt (II)-based LDH nanocages in oncology, laying a foundation for future innovations in tumor immunotherapy.
25
Inflammation and tumor progression: signaling pathways and targeted intervention
Huakan Zhao, Lei Wu, Guifang Yan et al. · Signal Transduction and Targeted Therapy · 2021 · 2.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Yuan Pan, Rui Lin, Yinjuan Chen et al. · Journal of the American Chemical Society · 2018 · 1.2K citations
Tom20 senses iron-activated ROS signaling to promote melanoma cell pyroptosis
Bo Zhou, Jia-yuan Zhang, Xian-shuo Liu et al. · Cell Research · 2018 · 668 citations · Full text